About us
SCHMIDT Capital Advisors: Competence and experience.
SCHMIDT Capital Advisors: Competence and experience
Capital raises nearly always come with a range of questions that the company and its management need to answer: What makes our company unique to investors? What is the best way to present our investment case? Should we provide financial guidance in the prospectus, and if so, how? How do we obtain authorization from the general assembly without alarming the market? What are our priorities if we can’t raise the full amount we need? What about employee incentive programs? What about the board’s composition? Is it time for us to switch from local GAAP to IFRS?
At SCHMIDT Capital Advisors, our mission is to offer corporate finance advisory services that are not just technically excellent but also enriched by decades of experience from our own careers as senior executives and board members in growth companies.
You would be hard-pressed to think of a financial, strategic, regulatory, governance, or technical problem we have not faced at some point in our careers. All those hard-won lessons will be available to you as we embark on your capital-raising journey.
Jakob began his career in Corporate Finance at Carnegie Bank and later became a pioneer in the Danish biotech industry, holding CEO and board roles at Pharmexa, Curalogic, Inoxell, and other biotech companies. He subsequently served as SVP and EVP at Falck, a global healthcare services company, where he led numerous M&A transactions across Europe, the Middle East, Asia, and Sub-Saharan Africa. In 2019, Jakob returned to financial advisory services, initially collaborating with Translution Capital, before founding SCHMIDT Capital Advisors in 2024. He is currently the chairman of the board of directors of the LINX Association, an organization dedicated to enhancing Danish industry’s access to advanced material sciences. The LINX Association also hosts the Secretariat for the Industrial Use of Research Infrastructure, funded by the Danish Agency for Higher Education and Science (Uddannelses- og Forskningsstyrelsen).
Jakob holds an M.Sc. degree in Economics and Business Administration (Finance) from Copenhagen Business School, obtained in 1992. He pursued Ph.D. studies at the Institute of Finance, Copenhagen Business School, studied medicine at Aarhus University, and studied international economics and finance at the graduate level at Brandeis University in Boston. Previous board positions include chairman roles at Curalogic A/S, Gemvax AS, Gudme Raaschau Vision A/S, Falck Sri Lanka Inc., and Pharmexa-Epimmune Inc., as well as a board member role at Inoxell A/S.
Jakob Schmidt.
Founder of Schmidt Capital Advisors.
Jakob began his career in Corporate Finance at Carnegie Bank and later became a pioneer in the Danish biotech industry, holding CEO and board roles at Pharmexa, Curalogic, Inoxell, and other biotech companies. He subsequently served as SVP and EVP at Falck, a global healthcare services company, where he led numerous M&A transactions across Europe, the Middle East, Asia, and Sub-Saharan Africa. In 2019, Jakob returned to financial advisory services, initially collaborating with Translution Capital, before founding SCHMIDT Capital Advisors in 2024. He is currently the chairman of the board of directors of the LINX Association, an organization dedicated to enhancing Danish industry’s access to advanced material sciences. The LINX Association also hosts the Secretariat for the Industrial Use of Research Infrastructure, funded by the Danish Agency for Higher Education and Science (Uddannelses- og Forskningsstyrelsen).
Jakob holds an M.Sc. degree in Economics and Business Administration (Finance) from Copenhagen Business School, obtained in 1992. He pursued Ph.D. studies at the Institute of Finance, Copenhagen Business School, studied medicine at Aarhus University, and studied international economics and finance at the graduate level at Brandeis University in Boston. Previous board positions include chairman roles at Curalogic A/S, Gemvax AS, Gudme Raaschau Vision A/S, Falck Sri Lanka Inc., and Pharmexa-Epimmune Inc., as well as a board member role at Inoxell A/S.
SCA combines 30 years of corporate finance experience from both sides of the table.
We have advised on multiple Copenhagen Stock Exchange IPOs, rights issues and private placements in first generation biotech companies such as NeuroSearch, Bavarian Nordic, Curalogic and Pharmexa, as well as recent First North/Spotlight transaction’s like Bawat and BioSergen’s IPO’s, or Cessatech and ExpreS2ion Biotech’s right issues. Through co-ownership of Nordic Underwriting (www.nordicunderwriting.com), Schmidt Capital Advisors has strong ties to the Scandinavian underwriter community, crucial to a successful rights issue.